Cart
sales@molnova.com
Evobrutinib
CAS No. 1415823-73-2
Evobrutinib( M2951 | MSC2364447C | MSC 2364447 )
Catalog No. M11730 CAS No. 1415823-73-2
A potent, highly selective BTK inhibitor for the treatment of various autoimmune disorders.Rheumatoid ArthritisPhase 2 Clinical
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 85 | In Stock |
|
| 5MG | 77 | In Stock |
|
| 10MG | 123 | In Stock |
|
| 25MG | 227 | In Stock |
|
| 50MG | 323 | In Stock |
|
| 100MG | 461 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 995 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEvobrutinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, highly selective BTK inhibitor for the treatment of various autoimmune disorders.Rheumatoid ArthritisPhase 2 Clinical
-
DescriptionA potent, highly selective BTK inhibitor for the treatment of various autoimmune disorders.Rheumatoid Arthritis Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsM2951 | MSC2364447C | MSC 2364447
-
PathwayTyrosine Kinase
-
TargetBTK
-
RecptorBTK
-
Research AreaInflammation/Immunology
-
IndicationRheumatoid Arthritis
Chemical Information
-
CAS Number1415823-73-2
-
Formula Weight429.51418
-
Molecular FormulaC25H27N5O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: 6.4 mg/mL (Need ultrasonic)
-
SMILESC=CC(N1CCC(CNC2=NC=NC(N)=C2C3=CC=C(OC4=CC=CC=C4)C=C3)CC1)=O
-
Chemical Name2-Propen-1-one, 1-[4-[[[6-amino-5-(4-phenoxyphenyl)-4-pyrimidinyl]amino]methyl]-1-piperidinyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Patent US20140162983 example 0174.
molnova catalog
related products
-
Tolebrutinib
Tolebrutinib is a potent, selective, orally active and brain-penetrant Bruton tyrosine kinase (BTK) inhibitor(IC50s of 0.4 and 0.7 nM in Ramos B cells and in HMC microglia cells, respectively).
-
BDTX-189
BDTX-189 is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations(KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively). BDTX-189 exhibits anticancer activity.
-
Larotinib
Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.
